Cabometyx sNDA receives FDA priority review for previously treated radioactive iodine-refractory differentiated thyroid cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A supplemental New Drug Application for Cabometyx (cabozantinib) was granted FDA priority review as a treatment for patients 12 years and older with differentiated thyroid cancer who have progressed following prior therapy and are radioactive iodine-refractory (if radioactive iodine is appropriate). 

Cabometyx is sponsored by Exelixis Inc. 

The FDA granted Priority Review designation and assigned a Prescription Drug User Fee Act  target action date of Dec. 4, 2021.

The sNDA is based on the results of COSMIC-311, a phase III pivotal trial evaluating Cabometyx versus placebo in patients with radioactive iodine-refractory DTC who progressed after up to two prior vascular endothelial growth factor receptor (VEGFR)-targeted therapies. 

At a planned interim analysis, Cabometyx met one of the trial’s primary endpoints, demonstrating a significant improvement in progression-free survival versus placebo. 

In February 2021, the FDA granted Breakthrough Therapy Designation to Cabometyx as a potential treatment for patients with DTC that has progressed following prior therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate) based on these results. Detailed study findings were presented at the 2021 American Society of Clinical Oncology annual meeting and were published by The Lancet Oncology in July 2021.

Table of Contents


President Joe Biden has announced his intent to appoint Monica Bertagnolli as the 16th director of the National Cancer Institute—and the first woman and first chair of a clinical trials cooperative group to be named to the role.The White House announcement Aug. 10 comes nearly three weeks after news of Bertagnolli’s appointment leaked out on Twitter and in the press (The Cancer Letter, July 21, 2022).
Can you imagine, as a radiation oncologist, you have to shelter your patients in a Co-60 vault to protect them from missiles, provide them with water by melting snow, feed them, keep them warm by using a backup power generator, and evacuate them just two hours before the missile destroys the radiation oncology department? 
Research shows that cancer patients who receive navigation have improved survival, access to advanced care like clinical trials, and services like genetic testing and palliative care. Navigation often results in increased screening and patients receiving treatment sooner, resulting in improved quality of life and more cancer-free days.